SNBIF Quote, Financials, Valuation and Earnings

Healios KK has a net margin of -- compared to SanBio's net margin of -107.23%. SanBio's return on equity of -- beat Healios KK's return on equity of -137.21%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than Healios KK, analysts believe SanBio is more attractive than Healios KK.

SanBio has a beta of -0.336, which suggesting that the stock is 133.637% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Healios KK quarterly revenues of $3.2M. SanBio's net income of -$5.8M is lower than Healios KK's net income of -$3.4M. Notably, SanBio's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 97.52x versus 32.00x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -- compared to SanBio's net margin of -5.57%. SanBio's return on equity of -- beat PeptiDream's return on equity of 34.66%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than PeptiDream, analysts believe SanBio is more attractive than PeptiDream.

SanBio has a beta of -0.336, which suggesting that the stock is 133.637% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.389%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than PeptiDream quarterly revenues of $36.8M. SanBio's net income of -$5.8M is lower than PeptiDream's net income of -$2.1M. Notably, SanBio's price-to-earnings ratio is -- while PeptiDream's PE ratio is 20.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 97.52x versus 7.14x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -- compared to SanBio's net margin of 12.96%. SanBio's return on equity of -- beat Nxera Pharma's return on equity of -5.58%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that SanBio has higher upside potential than Nxera Pharma, analysts believe SanBio is more attractive than Nxera Pharma.

SanBio has a beta of -0.336, which suggesting that the stock is 133.637% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.345%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SanBio pays -- of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Nxera Pharma quarterly revenues of $62.4M. SanBio's net income of -$5.8M is lower than Nxera Pharma's net income of $8.1M. Notably, SanBio's price-to-earnings ratio is -- while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 97.52x versus 2.79x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -- compared to SanBio's net margin of 7.83%. SanBio's return on equity of -- beat Takeda Pharmaceutical's return on equity of 4.01%.

SanBio has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $16.03 which suggests that it could grow by 22.35%. Given that Takeda Pharmaceutical has higher upside potential than SanBio, analysts believe Takeda Pharmaceutical is more attractive than SanBio.

SanBio has a beta of -0.336, which suggesting that the stock is 133.637% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.209%.

SanBio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Takeda Pharmaceutical offers a yield of 4.72% to investors and pays a quarterly dividend of $0.33 per share. SanBio pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 199.34% of its earnings as a dividend.

SanBio quarterly revenues are --, which are smaller than Takeda Pharmaceutical quarterly revenues of $7.9B. SanBio's net income of -$5.8M is lower than Takeda Pharmaceutical's net income of $619.7M. Notably, SanBio's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 21.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SanBio is 97.52x versus 1.38x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.